Previous Article
PDF
Standard view
Export citation
Share
Vol.16 No.4
July, 2022
Frequency : Quarterly
pISSN 1976-2283
eISSN 2005-1212 
Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
| Yong Chan Lee |
Professor of Medicine Director, Gastrointestinal Research Laboratory Veterans Affairs Medical Center, Univ. California San Francisco San Francisco, USA |
| Jong Pil Im | Seoul National University College of Medicine, Seoul, Korea |
| Robert S. Bresalier | University of Texas M. D. Anderson Cancer Center, Houston, USA |
| Steven H. Itzkowitz | Mount Sinai Medical Center, NY, USA |
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
Split Viewer
Sung Wook Hwang 
Correspondence to:Sung Wook Hwang
ORCID https://orcid.org/0000-0002-6981-7575
E-mail hsw903@gmail.com
See “Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease: A Population-Based Nationwide Inception Cohort Study” by Su Young Kim, et al. on page 555, Vol. 16, No. 4, 2022
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gut Liver 2022; 16(4): 495-496
Published online July 15, 2022 https://doi.org/10.5009/gnl220279
Copyright © Gut and Liver.
Inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, is a chronic systemic disease that predominantly affects the gastrointestinal tract.1 Patients with IBD are known to be at increased risk of venous thromboembolism (VTE), similar to that of those with other immune-mediated inflammatory diseases.2,3 In accordance with the increasing incidence and prevalence of IBD around the world,4 IBD-related VTE is becoming an important issue. The risk for VTE in patients with IBD has been reported to be 2- to 3-fold than patients without IBD.1,3 Pulmonary embolism (PE) and deep vein thrombosis (DVT) of the leg are known to be the most common sites of VTE, but unusual sites of VTE, such as cerebral vein thrombosis, have also been reported.1 However, most published data regarding VTE in patients with IBD are from Western patients, while studies that focus on Asian IBD patients are very rare. Prophylaxis for VTE in Asian IBD patients has also been controversial.
Following current evidence, Western guidelines such as the European Crohn’s and Colitis Organisation consensus and the American College of Gastroenterology clinical guideline recommend that antithrombotic prophylaxis to prevent VTE should be considered in IBD patients with risk factors for VTE, especially in hospitalized patients with acute severe disease.3,5 The risk of VTE in patients with IBD is particularly apparent during hospitalization and disease flare-up. Other risk factors for VTE such as surgery, pregnancy, obesity, and old age are also well-established.3,5 Recently, an international consensus on the prevention of venous and arterial thrombosis in patients with IBD was released.1 In the consensus, thromboprophylaxis was strongly recommended in hospitalized patients regardless of the cause of hospitalization. Even in remission, hospitalized patients with IBD were reported to have higher risk of VTE compared with those without IBD. The consensus, furthermore, recommended that prophylaxis should be maintained during the hospitalization period and even after discharge in patients with strong risk factors for VTE.1 If the patient with active IBD is ambulatory but has known risk factors for VTE, prophylaxis can be considered on a case-by-case basis, following the consensus. However, it was not clear whether anticoagulation prophylaxis might be justified in East Asian patients with IBD as the studies comparing the general risk of VTE in IBD patients with that in those without IBD were scarce in East Asia.
To address this gap in the literature, in the current issue of
The risk of VTE in East Asian patients with IBD seems to be underestimated by clinicians, but current data from the recent studies concur with the Western data. Thus, it seems to be reasonable, with the current evidence, that antithrombotic prophylaxis is considered in all hospitalized patients and selected patients with high-risk factors, in line with Western guidelines.1,3,5 To more clearly support the strategy of VTE prophylaxis in East Asian patients, a well-designed prospective study focusing on the effect of thromboprophylaxis on VTE outcome is warranted.
No potential conflict of interest relevant to this article was reported.
Gut and Liver 2022; 16(4): 495-496
Published online July 15, 2022 https://doi.org/10.5009/gnl220279
Copyright © Gut and Liver.
Sung Wook Hwang
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Correspondence to:Sung Wook Hwang
ORCID https://orcid.org/0000-0002-6981-7575
E-mail hsw903@gmail.com
See “Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease: A Population-Based Nationwide Inception Cohort Study” by Su Young Kim, et al. on page 555, Vol. 16, No. 4, 2022
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, is a chronic systemic disease that predominantly affects the gastrointestinal tract.1 Patients with IBD are known to be at increased risk of venous thromboembolism (VTE), similar to that of those with other immune-mediated inflammatory diseases.2,3 In accordance with the increasing incidence and prevalence of IBD around the world,4 IBD-related VTE is becoming an important issue. The risk for VTE in patients with IBD has been reported to be 2- to 3-fold than patients without IBD.1,3 Pulmonary embolism (PE) and deep vein thrombosis (DVT) of the leg are known to be the most common sites of VTE, but unusual sites of VTE, such as cerebral vein thrombosis, have also been reported.1 However, most published data regarding VTE in patients with IBD are from Western patients, while studies that focus on Asian IBD patients are very rare. Prophylaxis for VTE in Asian IBD patients has also been controversial.
Following current evidence, Western guidelines such as the European Crohn’s and Colitis Organisation consensus and the American College of Gastroenterology clinical guideline recommend that antithrombotic prophylaxis to prevent VTE should be considered in IBD patients with risk factors for VTE, especially in hospitalized patients with acute severe disease.3,5 The risk of VTE in patients with IBD is particularly apparent during hospitalization and disease flare-up. Other risk factors for VTE such as surgery, pregnancy, obesity, and old age are also well-established.3,5 Recently, an international consensus on the prevention of venous and arterial thrombosis in patients with IBD was released.1 In the consensus, thromboprophylaxis was strongly recommended in hospitalized patients regardless of the cause of hospitalization. Even in remission, hospitalized patients with IBD were reported to have higher risk of VTE compared with those without IBD. The consensus, furthermore, recommended that prophylaxis should be maintained during the hospitalization period and even after discharge in patients with strong risk factors for VTE.1 If the patient with active IBD is ambulatory but has known risk factors for VTE, prophylaxis can be considered on a case-by-case basis, following the consensus. However, it was not clear whether anticoagulation prophylaxis might be justified in East Asian patients with IBD as the studies comparing the general risk of VTE in IBD patients with that in those without IBD were scarce in East Asia.
To address this gap in the literature, in the current issue of
The risk of VTE in East Asian patients with IBD seems to be underestimated by clinicians, but current data from the recent studies concur with the Western data. Thus, it seems to be reasonable, with the current evidence, that antithrombotic prophylaxis is considered in all hospitalized patients and selected patients with high-risk factors, in line with Western guidelines.1,3,5 To more clearly support the strategy of VTE prophylaxis in East Asian patients, a well-designed prospective study focusing on the effect of thromboprophylaxis on VTE outcome is warranted.
No potential conflict of interest relevant to this article was reported.
pISSN 1976-2283
eISSN 2005-1212
Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
| Yong Chan Lee |
Professor of Medicine Director, Gastrointestinal Research Laboratory Veterans Affairs Medical Center, Univ. California San Francisco San Francisco, USA |
| Jong Pil Im | Seoul National University College of Medicine, Seoul, Korea |
| Robert S. Bresalier | University of Texas M. D. Anderson Cancer Center, Houston, USA |
| Steven H. Itzkowitz | Mount Sinai Medical Center, NY, USA |
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
